Professor, Pediatrics, Oregon Health and Science University School of Medicine

Pediatrics

Markus Grompe practices Pediatrics. Markus C. Grompe, MD is a published doctor and has 101 publications published. The lastest was: 'Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.'

Publications

---

• Stem cells versus plasticity in liver and pancreas regeneration.
• Oxymetholone Therapy of Fanconi Anemia Suppresses Osteopontin Transcription and Induces Hematopoietic Stem Cell Cycling.
• Bipotential Adult Liver Progenitors Are Derived from Chronically Injured Mature Hepatocytes.
• Extensive double humanization of both liver and hematopoiesis in FRGN mice.
• The organoid-initiating cells in mouse pancreas and liver are phenotypically and functionally similar.
• Liver stem cells, where art thou?
• Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease.
• Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype.
• Clonal tracing of Sox9+ liver progenitors in oval cell injury.
• Pharmacologic inhibition of L-tyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU).
• Selection and evaluation of clinically relevant AAV variants in a xenograft liver model.
• Evaluation of resveratrol and N-acetylcysteine for cancer chemoprevention in a Fanconi anemia murine model.
• Fancd2 and p21 function independently in maintaining the size of hematopoietic stem and progenitor cell pool in mice.
• Mice with human livers.
• Response to "Can 'humanized' mice improve drug development in the 21st century?".
• A Therapy for Liver Failure Found in the JNK Yard.
• Erratum to: Transcriptomes of the major human pancreatic cell types.
• Generation of islet-like cells from mouse gall bladder by direct ex vivo reprogramming.
• p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver.
• In Vivo Selection of Transplanted Hepatocytes by Pharmacological Inhibition of Fumarylacetoacetate Hydrolase in Wild-type Mice.
• Human pancreatic cancer fusion 2 (HPC2) 1-B3: A novel monoclonal antibody to screen for pancreatic ductal dysplasia.
• Tissue stem cells: new tools and functional diversity.
• AAV-mediated gene targeting is significantly enhance by transient inhibition of NHEJ or the proteasome in vivo.
• Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
• Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
• The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.
• The pathophysiology and treatment of hereditary tyrosinemia type 1.
• Fanconi anemia and DNA repair.
• Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase.
• Loss of p27(Kip1) enhances the transplantation efficiency of hepatocytes transferred into diseased livers.
• Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9.
• Liver repopulation for the treatment of metabolic diseases.
• Mouse liver goes human: a new tool in experimental hepatology.
• Prenatal diagnosis of succinic semialdehyde dehydrogenase deficiency: increased accuracy employing DNA, enzyme, and metabolite analyses.
• Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.
• Positional cloning of a novel Fanconi anemia gene, FANCD2.
• Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in Fanconi anemia group C.
• Liver repopulation and correction of metabolic liver disease by transplanted adult mouse pancreatic cells.
• Mechanistic inferences from the crystal structure of fumarylacetoacetate hydrolase with a bound phosphorus-based inhibitor.
• Purified hematopoietic stem cells can differentiate into hepatocytes in vivo.
• DNA replication is required To elicit cellular responses to psoralen-induced DNA interstrand cross-links.
• Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6.
• Therapeutic liver repopulation for the treatment of metabolic liver diseases.
• Localization of the Fanconi anemia complementation group D gene to a 200-kb region on chromosome 3p25.3.
• Phenotypic correction of Fanconi anemia group C knockout mice.
• The repopulation potential of hepatocyte populations differing in size and prior mitotic expansion.
• In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I.
• In vivo selection of wild-type hematopoietic stem cells in a murine model of Fanconi anemia.
• Gene structure, chromosomal location, and expression pattern of maleylacetoacetate isomerase.
• Principles of therapeutic liver repopulation.
• Identification of the mutation in the alkaptonuria mouse model. Mutations in brief no. 216. Online.
• Embryonic stem cells can be used to construct hybrid cell lines containing a single, selectable murine chromosome.
• Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice.
• Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.
• Subtyping analysis of Fanconi anemia by immunoblotting and retroviral gene transfer.
• Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I.
• DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function.
• Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes.
• Molecular biology of Fanconi anemia: implications for diagnosis and therapy.
• Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells.
• Complementation group assignments in Fanconi anemia fibroblast cell lines from North America.
• Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I.
• Immortalization of four new Fanconi anemia fibroblast cell lines by an improved procedure.
• Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I.
• Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene.
• Report of the sixth international workshop on human chromosome 3 mapping 1995.
• Clinical variability of Fanconi anemia (type C) results from expression of an amino terminal truncated Fanconi anemia complementation group C polypeptide with partial ...
• Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I.
• Spontaneous deletion in the FMR1 gene in a patient with fragile X syndrome and cherubism.
• Cloning and characterization of a human cDNA (INPPL1) sharing homology with inositol polyphosphate phosphatases.
• A common mutation in the FACC gene causes Fanconi anaemia in Ashkenazi Jews.
• Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I.
• Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice.
• The rapid detection of unknown mutations in nucleic acids.
• Fanconi anemia cells have a normal gene structure for topoisomerase I.
• Microphthalmia with linear skin defects (MLS) syndrome: clinical, cytogenetic, and molecular characterization.
• The Ashkenazi Jewish Fanconi anemia mutation: incidence among patients and carrier frequency in the at-risk population.
• A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I.
• Efficiency of insertion versus replacement vector targeting varies at different chromosomal loci.
• Rapid nonradioactive assay for the detection of the common French Canadian tyrosinemia type I mutation.
• Microcell mediated chromosome transfer maps the Fanconi anaemia group D gene to chromosome 3p.
• Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I.
• A functionally active retrovirus vector for gene therapy in Fanconi anemia group C.
• A comparative study on steroid sulfatase and arylsulfatase C in fibroblast clones from 45,X/47,XXX and 69,XXY.
• RNA virus expression during and after methylnitrosourea-induced T-cell leukemogenesis in mice.
• Detection of new mutation disease in man and mouse.
• Scanning detection of mutations in human ornithine transcarbamoylase by chemical mismatch cleavage.
• Ectopic correction of ornithine transcarbamylase deficiency in sparse fur mice.
• Molecular detection and correction of ornithine transcarbamylase deficiency.
• Characterization of a murine gene expressed from the inactive X chromosome.
• Mutations in the Escherichia coli dnaG gene suggest coupling between DNA replication and chromosome partitioning.
• A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome.
• Fidelity of targeted recombination in human fibroblasts and murine embryonic stem cells.
• Gene therapy in man and mice: adenosine deaminase deficiency, ornithine transcarbamylase deficiency, and Duchenne muscular dystrophy.
• Improved molecular diagnostics for ornithine transcarbamylase deficiency.
• Point mutations and polymorphisms in the human dystrophin gene identified in genomic DNA sequences amplified by multiplex PCR.
• The sulfatase gene family: cross-species PCR cloning using the MOPAC technique.
• Retroviral-mediated gene transfer of human ornithine transcarbamylase into primary hepatocytes of spf and spf-ash mice.
• Identification of point mutations in the steroid sulfatase gene of three patients with X-linked ichthyosis.
• Nucleotide sequence of a cDNA encoding murine fumarylacetoacetate hydrolase.

Doctors Specialties

---

• Clinical Biochemical Genetics
• Clinical Genetics
• Pediatrics

Accepted Insurances

---

Education

---

• Oregon Health & Science University
• University of Ulm Faculty of Medicine

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Susan Hayflick, MD This Doctor is OpenDoctor Recommended.
	Dr. Tammy A. Heskett, MD This Doctor is OpenDoctor Recommended.
	Dr. David M. Koeller, MD This Doctor is OpenDoctor Recommended.
	Dr. Alan F. Rope, MD This Doctor is OpenDoctor Recommended.
	Dr. Marlo L. McIlraith, MD This Doctor is OpenDoctor Recommended.
	Dr. Corey A. Fish, MD
	Dr. Edward L. Ruden, MD This Doctor is OpenDoctor Recommended.
	Dr. Jonathan Zonana, MD This Doctor is OpenDoctor Recommended.
	Dr. Svati Valia Nicholson, MD
	Dr. Cristina L. Swanson, MD
	Dr. Jodeanne K. Bellant, MD This Doctor is OpenDoctor Recommended.
	Dr. Don H. Lagrone, MD This Doctor is OpenDoctor Recommended.
	Dr. Lane H. Miller, MD
	Dr. Lucy M. Amory, MD
	Dr. Robb E. Moses, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert J. Steelman, MD This Doctor is OpenDoctor Recommended.
	Dr. George Anadiotis, DO This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog